Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA

Key facts

Sponsor

Masonic Cancer Center, University of Minnesota

Principal Investigator

Jakub Tolar, M.D., Ph.D., MD

Masonic Cancer Center, University of Minnesota

Intervention

Campath 1H(drug)

Enrollment

36 enrolled

Eligibility

70 years · All sexes

Timeline

2007 – 2016

Study locations (1)

• Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Dyskeratosis congenita

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT06817590
  Nucleoside Therapy in Patients With Telomere Biology Disorders
  Suneet Agarwal
• ACTIVE NOT RECRUITINGPHASE2NCT01659606
  Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita
  Boston Children's Hospital

See all trials for Dyskeratosis congenita →